JAK Inhibitor vs TL1A Inhibitor — Immunology Deal Terms Comparison
Market Analysis
In immunology, JAK Inhibitor and TL1A Inhibitor represent two of the most actively transacted modalities. At Phase 2, JAK Inhibitor deals carry a median total deal value of $2.7B with $513M upfront, compared to $3.5B total value and $676M upfront for TL1A Inhibitor. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. JAK Inhibitor development milestones average $432M versus $570M for TL1A Inhibitor. Commercial milestones are $973M for JAK Inhibitor and $1.3B for TL1A Inhibitor. Royalty rates range from 13.5%-22.5% for JAK Inhibitor and 14.7%-24.5% for TL1A Inhibitor.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do JAK Inhibitor and TL1A Inhibitor deal terms compare in immunology?
Which modality commands higher royalty rates: JAK Inhibitor or TL1A Inhibitor?
How do milestone structures differ between JAK Inhibitor and TL1A Inhibitor?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.